2. Academic Validation
  3. Perturbations in podocyte transcriptome and biological pathways induced by FSGS associated circulating factors

Perturbations in podocyte transcriptome and biological pathways induced by FSGS associated circulating factors

  • Ann Transl Med. 2023 Jun 30;11(9):315. doi: 10.21037/atm-22-3670.
Priyanka Rashmi # 1,  Tara K Sigdel # 1,  Dmitry Rychkov 1,  Izabella Damm 1,  Andrea Alice Da Silva 2,  Flavio Vincenti 1,  Andre L Lourenco 3,  Charles S Craik 3,  Jochen Reiser 4,  Minnie M Sarwal 1
Affiliations

Affiliations

  • 1 Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
  • 2 Department of Immunology, Laboratory of Autoimmunity and Immunoregulation, Fluminense Federal University, Niteroi, Brazil.
  • 3 Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
  • 4 Department of Medicine, Rush University Medical Center, Chicago, IL, USA.
  • # Contributed equally.
PMID: 37404982 DOI: 10.21037/atm-22-3670
Abstract

Background: Focal segmental glomerulosclerosis (FSGS) is frequently associated with heavy proteinuria and progressive renal failure requiring dialysis or kidney transplantation. However, primary FSGS also has a ~40% risk of recurrence of disease in the transplanted kidney (rFSGS). Multiple circulating factors have been identified to contribute to the pathogenesis of primary and rFSGS including soluble urokinase-type plasminogen activator receptor (suPAR) and patient-derived CD40 autoantibody (CD40autoAb). However, the downstream effector pathways specific to individual factors require further study. The tumor necrosis factor, TNF pathway activation by one or more circulating factors present in the sera of patients with FSGS has been supported by multiple studies.

Methods: A human in vitro model was used to study podocyte injury measured as the loss of actin stress fibers. Anti-CD40 autoantibody was isolated from FSGS patients (recurrent and non-recurrent) and control patients with ESRD due to non-FSGS related causes. Two novel human antibodies-anti-uPAR (2G10) and anti-CD40 antibody (Bristol Meyer Squibb, 986090) were tested for their ability to rescue podocyte injury. Podocytes treated with patient derived antibody were transcriptionally profiled using whole human genome microarray.

Results: Here we show that podocyte injury caused by sera from FSGS patients is mediated by CD40 and suPAR and can be blocked by human anti-uPAR and anti-CD40 antibodies. Transcriptomic studies to compare the molecules and pathways activated in response to CD40 autoantibody from rFSGS patients (rFSGS/CD40autoAb) and suPAR, identified unique inflammatory pathways associated with FSGS injury.

Conclusions: We identified several novel and previously described genes associated with FSGS progression. Targeted blockade of suPAR and CD40 pathways with novel human antibodies showed inhibition of podocyte injury in FSGS.

Keywords

CD40; autoantibody; focal segmental glomerulosclerosis (FSGS); kidney transplantation; soluble urokinase-type plasminogen activator receptor (suPAR).

Figures
Products